Clene Inc. (NASDAQ: CLNN) Continues Development of Lead Drug Candidate CNM Au8(R) for Neurodegenerative Diseases including Parkinson’s Disease
April 22, 2024
In recognition of April as Parkinson’s Disease Awareness Month, IBN is highlighting Clene (NASDAQ: CLNN), a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including Parkinson’s disease (“PD”), amyotrophic lateral sclerosis (“ALS”), and multiple sclerosis (“MS”). Clene is developing its lead drug candidate CNM-Au8(R) for potential […]
InvestorNewsBreaks – Clene Inc. (NASDAQ: CLNN) Announces Study Results for CNM-Au8 as Multiple Sclerosis Treatment Presented at AAN Conference
April 17, 2024
Clene (NASDAQ: CLNN), a late clinical-stage biopharmaceutical company, and its wholly owned subsidiary Clene Nanomedicine Inc., announced that results from a phase 2 Visionary-MS long-term extension (“LTE”) study have been presented at the 2024 American Academy of Neurology (“AAN”) annual meeting. The data, which demonstrates improved clinical, functional and structural outcomes associated with daily oral […]
InvestorNewsBreaks – Clene Inc. (NASDAQ: CLNN) Looking to Advance Discussions for Accelerated Approval, New NDA for CNM-Au8(R) in 2024
April 11, 2024
Clene (NASDAQ: CLNN), alongside its wholly owned subsidiary Clene Nanomedicine Inc., is a clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases. These include amyotrophic lateral sclerosis (“ALS”) and multiple sclerosis (“MS”). “Clene’s lead candidate, CNM-Au8(R), is a gold nanocrystal suspension that has emerged as a promising candidate […]
Clene Inc. (NASDAQ: CLNN) has Emerged as a Leader in the Neurodegenerative Field Utilizing a Novel Nanotherapeutic Drug
April 9, 2024
In a significant advancement for the treatment of neurodegenerative diseases, Clene (NASDAQ: CLNN) has innovated CNM-Au8, an oral nanotherapeutic designed to revitalize the brain’s mitochondrial function. The potential of this drug to treat multiple neurological diseases was highlighted during the latest episode of the “First In Human” podcast, hosted by Vial’s Executive Vice President of […]
Clene Inc. (NASDAQ: CLNN) Announces Publication of “Protein Corona Composition of Gold Nanocatalysts” in ACS Pharmacology & Translational Science
April 2, 2024
Clene (NASDAQ: CLNN) and its wholly owned subsidiary Clene Nanomedicine Inc., a clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis (“ALS”) and multiple sclerosis (“MS”), recently reported the publication of “Protein Corona Composition of Gold Nanocatalysts” in the journal ACS Pharmacology & Translational […]
Clene Inc. (NASDAQ: CLNN) Announces Operational Highlights for Lead Therapeutic Candidate for ALS and MS
March 26, 2024
Clene (NASDAQ: CLNN) and its wholly owned subsidiary Clene Nanomedicine Inc., a clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis (“ALS”) and multiple sclerosis (“MS”), recently announced its 2023 operational highlights for its lead candidate, along with future goals. Clene’s lead candidate, CNM-Au8(R), […]
InvestorNewsBreaks – Clene Inc.’s (NASDAQ: CLNN) Work in Nanotechnology Highlighted in ‘First in Human’ Podcast
March 19, 2024
Clene (NASDAQ: CLNN), a late clinical-stage biopharmaceutical company, was featured in a recent episode of First in Human, a biotech-focused podcast featuring interviews with industry leaders and investors to learn about their journeys to in-human clinical trials. Hosted by Vial EVP Rich McCormick, the podcast is available for on-demand listening on First in Human by […]
IBN Announces First in Human Podcast Featuring Clene Inc. CEO Rob Etherington
March 19, 2024
LOS ANGELES, March 19, 2024 (GLOBE NEWSWIRE) — via IBN – IBN, a multifaceted communications organization engaged in connecting public companies with the investment community, today announces that Rob Etherington, President, Director and CEO of late clinical-stage biopharmaceutical company Clene Inc. (NASDAQ: CLNN), recently appeared on First in Human, a biotech-focused podcast featuring interviews with industry leaders and investors […]
InvestorNewsBreaks – Clene Inc. (NASDAQ: CLNN) Announces Publication of Peer-Reviewed Research for Investigational Drug CNM-Au8(R)
March 15, 2024
Clene (NASDAQ: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, today announced the publication of peer-reviewed research, titled “Protein Corona Composition of Gold Nanocrystals.” The publication appeared in the journal ACS Pharmacology […]
InvestorNewsBreaks – Clene Inc. (NASDAQ: CLNN) Announces FY 2023 Results, Recent Operating Highlights
March 13, 2024
Clene (NASDAQ: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, today announced its full year 2023 financial results. In addition, the company provided recent operating highlights for the clinical programs in amyotrophic […]
InvestorNewsBreaks – Clene Inc. (NASDAQ: CLNN) Announces Participation at Upcoming 36th Annual Roth Conference
March 7, 2024
Clene (NASDAQ: CLNN), a late clinical-stage biopharmaceutical company, and its wholly owned subsidiary Clene Nanomedicine Inc., will be represented at this month’s annual Roth Conference. The conference will be held March 18–19, 2024, in Dana Point, California. According to the announcement, company officials are scheduled to present a fireside chat, slated to begin at 8 […]
InvestorNewsBreaks – Clene Inc. (NASDAQ: CLNN), Subsidiary Report Positive Clinical Results of CNM-Au8 Treatment at MS Forum
February 29, 2024
Clene (NASDAQ: CLNN), a late clinical-stage biopharmaceutical company, and its wholly owned subsidiary Clene Nanomedicine Inc., is reporting on the full clinical results for CNM-Au8(R), an investigational first-in-class therapy designed to improve central nervous system cells’ survival and function. Clene, which is focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, […]
InvestorNewsBreaks – Clene Inc.’s (NASDAQ: CLNN) CNM-Au8 Aiming to Address Neurodegenerative Diseases from a New Angle
February 27, 2024
Clene (NASDAQ: CLNN) is a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis (“ALS”), Parkinson’s and multiple sclerosis (“MS”). “The company’s lead drug candidate is CNM-Au8, an innovative nanomedicine uniting the principles of physics, chemistry, materials science, and biology to address neurodegenerative […]
InvestorNewsBreaks – Clene Inc. (NASDAQ: CLNN) Announces Statistically Significant Results from Independent Analyses of ALS Patient Data
February 22, 2024
Clene (NASDAQ: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, today reported new, significant survival results in amyotrophic lateral sclerosis (“ALS”) patients. According to the announcement, the results are from two independent […]
InvestorNewsBreaks – Clene Inc. (NASDAQ: CLNN) Eyes ‘Rarely Seen’ Clinically Significant Improvement in MS Patients
February 20, 2024
Clene (NASDAQ: CLNN) and its wholly owned subsidiary Clene Nanomedicine Inc., a clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, recently reported new results from a long-term open-label extension (“LTE”) of the VISIONARY-MS trial in participants with stable relapsing multiple sclerosis (“RMS”) totaling nearly three years of […]
Clene Inc. (NASDAQ: CLNN) Featured in Coverage of the 36th Annual Roth Conference
February 19, 2024
Clene Inc. (Nasdaq: CLNN), along with its subsidiaries and its wholly owned subsidiary Clene Nanomedicine Inc., is a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis, Parkinson’s disease and multiple sclerosis. CNM-Au8® is an investigational first-in-class therapy that improves central nervous system cells’ […]
Clene Inc. (NASDAQ: CLNN) Revolutionizes Approach to Restore Neuronal Health in Neurodegenerative Disease with CNM-Au8(R)
February 13, 2024
Neurodegenerative diseases pose a significant challenge in healthcare, yet treatment options remain limited. Clene (NASDAQ: CLNN), a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, is working on a potentially groundbreaking nanomedicine called CNM-Au8® that aims to revolutionize the approach to addressing nervous system failure associated […]
InvestorNewsBreaks – Clene Inc. (NASDAQ: CLNN) CEO Discusses MS Trial Results During Latest Proactive Interview
February 6, 2024
Clene (NASDAQ: CLNN) CEO Rob Etherington was the featured guest on a recent Proactive interview. According to an announcement, Etherington joined Proactive host Steve Darling to discuss recent news the company has released regarding results from its long-term, open-label extension (“LTE”) of the VISIONARY-MS trial. Clene is a late clinical-stage biopharmaceutical company focused on improving […]
Clene Inc. (NASDAQ: CLNN) Reports ‘Unprecedented,’ Statistically Significant Long-Term Clinical Improvements for VISIONARY-MS Trial Participants with Stable Relapsing-Remitting MS
February 6, 2024
Clene (NASDAQ: CLNN) and its wholly owned subsidiary Clene Nanomedicine Inc., a clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, recently reported new results from the open-label long-term extension (“LTE”) of the VISIONARY-MS trial (https://ibn.fm/5QSDO). This was a double-blind, placebo-controlled Phase 2 clinical trial comprised of participants […]
InvestorNewsBreaks – Clene Inc.’s (NASDAQ: CLNN) CNM-Au8 Produces ‘Significant and Very Promising Effect’ in Parkinson’s, MS Patients
February 2, 2024
Clene’s (NASDAQ: CLNN) lead drug candidate CNM-Au8 was the subject of two Phase 2a clinical trials, REPAIR-PD and REPAIR-MS, which evaluated the effects of CNM-Au8 on brain energy metabolite levels in participants with diagnoses of idiopathic Parkinson’s Disease (“PD”) and relapsing Multiple Sclerosis (“MS”), respectively. The REPAIR-PD and REPAIR-MS Phase 2 trials expanded the documented […]
Clene Inc. (NASDAQ: CLNN) Unites Physics, Chemistry, Material Science, and Biology to Address Neurodegenerative Diseases With The Company’s Unique CNM-Au8(R) Pipeline
January 30, 2024
Clene (NASDAQ: CLNN) is a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis (“ALS”), Parkinson’s disease, and multiple sclerosis (“MS”). The company’s lead drug candidate is CNM-Au8, an innovative nanomedicine uniting the principles of physics, chemistry, materials science, and biology to address […]
Clene Inc. (NASDAQ: CLNN) VISIONARY-MS Trial Data May Support CNM-Au8(R) as Long-Sought-After Multiple Sclerosis Treatment
January 22, 2024
Clene (NASDAQ: CLNN) and its wholly-owned subsidiary Clene Nanomedicine Inc., is a clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis (“ALS”) and multiple sclerosis (“MS”). The company recently reported new CNM-Au8(R) results from a long-term open-label extension (“LTE”) of the VISIONARY-MS trial in […]
InvestorNewsBreaks – Clene Inc. (NASDAQ: CLNN) Announces Significant Positive Results from LTE VISIONARY-MS Trial
January 8, 2024
Clene (NASDAQ: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including (“ALS”) and multiple sclerosis (“MS”), today reported new CNM-Au8(R) results from the long-term open label extension (“LTE”) of the VISIONARY-MS trial […]
Clene Inc.’s (NASDAQ: CLNN) Phase 2 REPAIR-PD and REPAIR-MD Trials Indicate CNM-Au8(R)’s Ability to Increase Key Brain Metabolites, Supporting Advancement to Phase 3 Trials
January 2, 2024
Energy metabolism involves the conversion of the potential energy contained in food-borne fuels, including some amino acids, glucose, lactate, fatty acids, and ethanol, among others, into chemical energy. Usually, this chemical energy exists in the form of adenosine triphosphate (“ATP”), the universal energy-containing molecule that powers most cellular functions, including brain function. ATP is produced […]
InvestorNewsBreaks – Clene Inc. (NASDAQ: CLNN) Announces New Data from HEALEY ALS Platform Trial, Provides Update on ALS Clinical Development Meeting with FDA
December 21, 2023
Clene (NASDAQ: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., today announced new data from the 12-month long-term open label extension (“OLE”) of the CNM-Au8(R) treatment arm in the HEALEY ALS Platform Trial. A key biomarker of neurodegeneration, Neurofilament Light Chain (“NfL”) is released from neurons following axonal injury, […]
How Clene Inc. (NASDAQ: CLNN) CNM-Au8(R) Takes Advantage of Gold Nanocrystals to Target Neurodegenerative Disorders
December 18, 2023
Also known simply as nerve cells, neurons are central to most – if not all – of the body’s normal functions, from breathing and talking to eating, thinking, and walking (https://ibn.fm/zWMUR). They support these activities by sending and receiving information between the brain and muscles, and are also responsible for receiving sensory input from the […]
InvestorNewsBreaks – Clene Inc. (NASDAQ: CLNN) Lead Drug Candidate Featured in Peer-Reviewed Publication Describing Brain Target Engagement in Neurodegenerative Diseases
December 14, 2023
Clene (NASDAQ: CLNN), a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis (“ALS”), Parkinson’s disease and multiple sclerosis (“MS”), along with subsidiary Clene Nanomedicine, is announcing the publication of a peer-reviewed article describing brain target engagement by CNM-Au8(R), the company’s lead drug […]
InvestorNewsBreaks – Clene Inc.’s (NASDAQ: CLNN) Long-Term Follow-Up Data Shows Significantly Improved Survival in ALS Patients
December 8, 2023
Clene (NASDAQ: CLNN), together with its wholly owned subsidiary Clene Nanomedicine Inc., recently provided operating highlights for its amyotrophic lateral sclerosis (“ALS”) clinical program. “In August, Clene reported a 24-month long-term data cut from the open-label extension (‘OLE’) of the RESCUE-ALS study as of July 2023, which showed a significant median survival benefit of 19.3 […]
The 2023 Nobel Prize in Chemistry’s Spotlight on Nanotechnology Shines Light on Clene Inc. (NASDAQ: CLNN) Efforts to Develop Catalytically Active Nanoparticles
December 8, 2023
The Royal Swedish Academy of Sciences (“the Academy”), which is responsible for awarding Nobel Prizes in Chemistry and Physics, decided to award this year’s Nobel Prize in Chemistry to Moungi G. Bawendi, Louis E. Brus, and Aleksey Yekimov for their efforts in discovering and synthesizing quantum dots, nanometer-sized semiconductor crystals that bring colored light to […]
InvestorNewsBreaks – Clene Inc. (NASDAQ: CLNN) Targeting Confirmatory Support for Existing ALS Trial Data with NIH-Funded EAP Study
December 1, 2023
Clene’s (NASDAQ: CLNN) wholly owned subsidiary Clene Nanomedicine Inc. and its collaborators, Columbia University and Synapticure, recently received a four-year grant totaling $45.1 million. The grant will support an Expanded Access Protocol (“EAP”) study investigating the safety and efficacy of Clene’s investigational product (“IP”), CNM-Au8, as a treatment for people with amyotrophic lateral sclerosis (“ALS”). […]
Clene Inc. (NASDAQ: CLNN) Capitalizing on the Promising Chemical and Therapeutic Properties of Nanocrystals to Address High Unmet Medical Needs
November 22, 2023
Nanotechnology has attracted a great deal of the scientific community’s attention thanks to its ability to deliver medicinally attractive nanoparticles (“NPs”) with promising performances that are directly attributable to such properties as ease of cellular uptake, stability, solubility, synthetic accessibility, and release pattern and cell penetration. Studies investigating the therapeutic capabilities of metallic NPs such […]
Clene Inc. (NASDAQ: CLNN) Reports Q3 2023 Financial Results, Recent Operating Highlights for Its ALS Clinical Program
November 16, 2023
Clene (NASDAQ: CLNN) and its wholly owned subsidiary Clene Nanomedicine Inc., a clinical-stage pharmaceutical company focused on the discovery, development, and commercialization of a pipeline of novel clean-surfaced nanotechnology therapeutics for the treatment of central nervous system disorders, including Amyotrophic Lateral Sclerosis (“ALS”), multiple sclerosis (“MS”), and Parkinson’s disease (“PD”), recently released its financial results […]
Clene Inc. (NASDAQ: CLNN) Among Grant Awardees Selected to Advance Scientific Research on ALS
November 10, 2023
In late December of 2021, President Biden signed into law H.R. 3537, the Accelerated Access to Critical Therapies for ALS Act (“Act for ALS”) (https://ibn.fm/oQbSk). The Act for ALS (amyotrophic lateral sclerosis), now public law, directs the Department of Health and Human Services through the Secretary to, among others, “award grants to participating entities for […]
InvestorNewsBreaks – Clene Inc. (NASDAQ: CLNN) Announces Q3 2023 Financial Results, Operating Highlights
November 7, 2023
Clene (NASDAQ: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., today released its third quarter 2023 financial results and provided recent operating highlights for its ALS clinical program. Among the highlights, the company reported statistically significant improved survival benefit of 19.3 months and significantly delayed clinical worsening in patients […]
Clene Inc. (NASDAQ: CLNN) Reports Improved Survival Status in ALS Patients Treated with CNM-Au8(R) on Follow-Up Analysis; Announces Peer-Reviewed Study
October 30, 2023
Amyotrophic lateral sclerosis (“ALS”), or Lou Gehrig’s disease, is a progressive and degenerative neuromuscular disease that destroys nerve cells known as motor neurons, which control voluntary muscle movement (https://ibn.fm/bgJGu). A fatal neurological disorder, ALS lowers the life expectancy of patients to two to five years post-diagnosis, although some patients may live longer, as was the […]
Clene Inc. (NASDAQ: CLNN) Announces Four-Year Grant to Support Expanded Access Protocol for CNM-Au8 From NINDS
October 25, 2023
Clene (NASDAQ: CLNN), a late clinical-stage biopharmaceutical company on a mission to transform the treatment of neurodegenerative diseases, recently announced that its wholly-owned subsidiary Clene Nanomedicine Inc., in collaboration with Columbia University and Synapticure, has been awarded a four-year grant totaling $45.1 million from the National Institute of Neurological Disorders and Stroke (“NINDS”). The grant […]
InvestorNewsBreaks – Clene Inc. (NASDAQ: CLNN) ‘Innovates’ Investigational Drug with Patented Nanotechnology
October 17, 2023
Clene (NASDAQ: CLNN), a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, announced that it has innovated its investigational drug, CNM-Au8(R), with nanotechnology. Clene is evaluating CNM-Au8(R) for the treatment of neurodegenerative disease, and the innovation reflects the growing importance of nanotechnology in the drug space. […]
Clene Inc. (NASDAQ: CLNN) Applies Patented Nanotechnology to Development of CNM-Au8(R), its Investigational Drug for ALS
October 16, 2023
October 2023 has turned into a month for the celebration of nanotechnology. On Wednesday, Oct. 4, 2023, three U.S.-based scientists, Moungi Bawendi, Louis Brus, and Aleksey Ekimov, were awarded the 2023 Nobel Prize in Chemistry for their discovery and synthesis of tiny clusters of atoms known as quantum dots, which are widely used today in […]
InvestorNewsBreaks – Clene Inc. (NASDAQ: CLNN) CEO Featured in Latest Episode of The Bell2Bell Podcast
October 10, 2023
Clene (NASDAQ: CLNN), a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, is featured in the latest Bell2Bell Podcast release. During the segment, podcast host Stuart Smith discusses the company with Clene president and CEO Rob Etherington, who explains Clene’s business model and provides an overview […]
InvestorNewsBreaks – Clene Inc. (NASDAQ: CLNN) Announces $45.1M NINDS Grant to Support Expanded Access Protocol for CNM-Au8(R) in ALS
October 5, 2023
Clene (NASDAQ: CLNN), through its wholly owned subsidiary Clene Nanomedicine Inc. in collaboration with Columbia University and Synapticure, was awarded a four-year grant totaling $45.1 million from the National Institute of Neurological Disorders and Stroke (“NINDS”), a division of the National Institutes of Health (“NIH”). The grant is to support an Expanded Access Protocol (“EAP”) […]